Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No meta-analysis is yet available for the risk of metabolic syndrome (MetS) following androgen deprivation therapy (ADT) for men with prostate cancer. To summarize the evidence for the link between ADT and MetS or its components quantitatively with a meta-analysis including all studies published to date. METHODS: PubMed and Embase were searched using predefined inclusion criteria to perform meta-analyses on the association between metabolic syndrome, hyperglycemia, diabetes, hypertension, dyslipidemia or obesity and androgen deprivation therapy in patients with prostate cancer. Random effects methods were used to estimate pooled relative risks (RRs) and 95% confidence intervals (CI). RESULTS: A total of nine studies was included. There was a positive association between ADT and risk of MetS (RR: 1.75 (95% CI: 1.27-2.41)). Diabetes was the only MetS component present in more than 3 studies, and also showed an increased risk following ADT (RR: 1.36 (95% CI: 1.17-1.58)). CONCLUSION: This is the first quantitative summary addressing the potential risk of MetS following ADT in men with PCa. The positive RRs indicate that there is a need to further elucidate how type and duration of ADT affect these increased risks of MetS and diabetes as the number of men with PCa treated with ADT is increasing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455 · cited 3×
“[6] USA Cohort GnRH agonist, orchiectomy Diabetes 26,570 on ADT.”
BackgroundInfluentialZimmet, P., Alberti, K. G. M. M., & Serrano Ríos, M. (2005) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(06)60742-1 · Cited by 864
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 3×
“For example, a small study showed that ADT preferentially increase subcutaneous rather than visceral abdominal fat and increase rather than decrease HDL cholesterol, which is in contrast with the traditionally described MetS [18].”
BackgroundResultKeating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Corona, G., Mannucci, E., Forti, G., & Maggi, M. (2009) · International Journal of Andrology · doi:10.1111/j.1365-2605.2008.00951.x · Cited by 223
STRUM, S. B., McDERMED, J. E., SCHOLZ, M. C., JOHNSON, H., & TISMAN, G. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00234.x · Cited by 215
Saad, F., Aversa, A., M. Isidori, A., & J. Gooren, L. (2012) · Current Diabetes Reviews · doi:10.2174/157339912799424573 · Cited by 148 · cited 1×
“Additionally, testosterone has been suggested to regulate cell lineage determination by promoting the myogenic and inhibiting the adipogenic lineage [36].”
Background
Cited by
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
TFOS DEWS II Sex, Gender, and Hormones Report
Sullivan, D. A., Rocha, E. M., Aragona, P., Clayton, J. A., Ding, J., Golebiowski, B., Hampel, U., McDermott, A. M., Schaumberg, D. A., Srinivasan, S., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.04.001 · Cited by 434
Yunfeng, G., Weiyang, H., Xueyang, H., Yilong, H., & Xin, G. (2017) · Medicine · doi:10.1097/md.0000000000007368 · Cited by 60
Tombal, B., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., Iversen, P., Braeckman, J., Heracek, J., Baron, B., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2017.08.103 · Cited by 26
“ADT also induces metabolic changes such as increased serum cholesterol and triglycerides, and peripheral resistance to insulin, which could lead to diabetes and cardiovascular disease.(3,6,7) In contrast, therapy with nonsteroidal antiandrogens such as bicalutamide have been shown to inhibit the androgen receptor with…”
Background
Metadata
- Authors
- Bosco, C., Crawley, D., Adolfsson, J., Rudman, S., & Van Hemelrijck, M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-03-20
- Volume
- 10
- Issue
- 3
- Pages
- e0117344
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2068407327
- Cited by
- 84
- References
- 7
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0117344
- The paper
- Bosco, C., Crawley, D., Adolfsson, J., Rudman, S., & Van Hemelrijck, M. (2015). Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0117344
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.